Academic groups
Design and run observational and cohort studies on longitudinal evidence, with infrastructure designed to be ready from the first day.
Neural Omega Research
Decoding the future of medicine.
- Open to
- Academia, patients, industry
- Science
- Molecular mimicry
- Standards
- FHIR · OMOP · EHDS
Infrastructure for new studies, discovery through molecular mimicry and our own research lines in advanced therapies. One continuous line of work, from the first evidence to the next generation of treatments.
Medicine has learned to treat autoimmunity. Neural Omega Research sets out to understand it: where pathogen and human proteins resemble each other, and what follows when the immune system cannot tell them apart.
From evidence to advanced therapies.
This is how our work is organised, in four stages: the studies that describe the biology, the discovery that identifies candidate targets, development alongside industry and our own research into new modalities.
- Stage 01/ 04
Evidence
Observational and cohort studies on consented, longitudinal data, open to academic groups and patient organisations.
Where it happensMAR Platform - Stage 02/ 04
Discovery
Candidate targets identified through molecular mimicry between pathogen and human proteins, from detection toward validation.
Where it happensMassa Suite - Stage 03/ 04
Development
Targets that pass validation will move into development alongside pharma R&D teams, with clear intellectual property boundaries.
Where it happensIn partnership with industry - Stage 04/ 04
Advanced therapies
Our own research lines explore advanced therapy medicinal products (ATMPs), informed by what molecular mimicry reveals.3
Where it happensNeural Omega R&D
Stage 01 / 04Evidence
Observational and cohort studies on consented, longitudinal data, open to academic groups and patient organisations.
Where it happensMAR Platform
Stage 02 / 04Discovery
Candidate targets identified through molecular mimicry between pathogen and human proteins, from detection toward validation.
Where it happensMassa Suite
Stage 03 / 04Development
Targets that pass validation will move into development alongside pharma R&D teams, with clear intellectual property boundaries.
Where it happensIn partnership with industry
Stage 04 / 04Advanced therapies
Our own research lines explore advanced therapy medicinal products (ATMPs), informed by what molecular mimicry reveals.3
Where it happensNeural Omega R&D
Stages describe how our work is organised. The status of each platform is set out on its own website.4
Two structures.
One resemblance.
When pathogen and human proteins share a segment, an immune response to the pathogen can also recognise the human protein. We study where this happens.
Fig. 02 · Molecular mimicry, schematic
- Level 01
Screen
Proteome-wide comparison of pathogen and human proteins reveals where they resemble each other.
- Level 02
Classify
Our models classify those resemblances by pattern and biological context.
- Level 03
Explore
We explore which resemblances may shape an immune response, and how to act on them.
Open to those who move science forward.
Patient organisations
Set research priorities with their own communities, on their own terms.
Public institutions
Structured evidence on disease burden, access to treatment and care pathways, across Spain and Europe.
Pharma and biotech
Discovery and development partnerships with clear intellectual property boundaries, full traceability and documentation built for regulated environments.
Rigorous by method. Accessible by design.
In-house infrastructure required0Our platforms are designed so that Neural Omega provides the cloud computing capacity, and no group needs its own servers.5
Speaks the standards
- HL7 FHIR
- OMOP CDM
- GDPR
- EHDS
Built to move between centres, countries and health systems.
- Powerful tools, simple interfaces
- The depth of a research platform behind interfaces the whole team can use, from the bench to the clinic.
- Consent first
- Participation is opt-in for every study. Data from Neural Omega Health enters research only with explicit, study-specific consent.1
- Separate by design
- Pharma partnerships operate under their own commercial and data model, apart from the health apps for patients and clinicians.
- Built for the European Health Data Space
- Designed for HL7 FHIR and OMOP, and for multi-centre, cross-border studies under the GDPR.2
Two platforms. One line of discovery.
MAR PlatformFor research groups and patient organisationsmarplatform.com
Studies on real-world evidence.
Research infrastructure to design and run observational and cohort studies on autoimmune disease, on consented, longitudinal data.
Massa SuiteFor pharma and biotechmassasuite.com
Discovery through molecular mimicry.
Proteome-scale detection of resemblance between pathogen and human proteins, for target identification and discovery partnerships.
Shape the future
of medicine with us.
Research groups, patient organisations, public institutions and pharma R&D teams are welcome to start a conversation.
- Neural Omega processes personal health data in accordance with Regulation (EU) 2016/679 (General Data Protection Regulation), within the European Union.
- Designed to follow the HL7 FHIR standard, the OMOP Common Data Model and the framework of Regulation (EU) 2025/327 on the European Health Data Space.
- Advanced therapy medicinal products as defined in Regulation (EC) No 1394/2007. Neural Omega’s own research lines in this field are exploratory.
- The pipeline describes the organisation of Neural Omega’s research activity. Product capabilities, availability and status are set out on each platform’s own website.
- Computing capacity is provided within the European Union. Specific conditions depend on each platform and on the size of each dataset.